Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie

[cafead]

via Fresh off the back of Myovant Sciences’ first FDA win for relugolix in prostate cancer late last year, the Swiss pharma can now add a second indication to its flagship drug's resume.

article source